GlassScriptPhysician profile
Amanda N Partin
NPI 1750890349
$5,489.61
in general payments reported to CMS, 2019-2025
24 companies · $556 in 2025
The $556 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,007 · 2022: $2,552 · 2023: $791 · 2024: $584 · 2025: $556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,930.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,684.97 | 2022 | |
| Novartis Pharmaceuticals Corporation | $662.72 | 2021-2025 | |
| Abbott Laboratories | $482.50 | 2021-2025 | Amplatzer Amulet, Cardiomems |
| Pfizer INC. | $407.97 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $288.85 | 2021-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $283.63 | 2022-2023 | Verquvo |
| Amgen INC. | $281.35 | 2021-2023 | Repatha |
| Esperion Therapeutics, INC. | $248.75 | 2021-2022 | |
| Boston Scientific Corporation | $229.34 | 2022-2025 | Watchman Flx, Watchman, Varithena Administration Pack |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $154.67 | 2021-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.22 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $113.04 | 2021-2023 | Xarelto |
| Amarin Pharma, INC. | $102.91 | 2021 | |
| Abiomed | $99.48 | 2024-2025 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $52.08 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $51.77 | 2023 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $48.85 | 2022-2023 | |
| Atricure, INC. | $46.97 | 2024 | |
| Kestra Medical Technology Services, INC. | $44.14 | 2025 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $23.06 | 2022 | |
| Lilly USA, LLC | $19.26 | 2025 | Zepbound, Mounjaro |
| Cleerly, INC. | $18.43 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Lexicon Pharmaceuticals, INC. | $15.65 | 2023 | Inpefa |
| Silk Road Medical, INC. | $14.00 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Partin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.